Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biomedical research

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    412 result(s) found for: Biomedical research. Displaying page 8 of 21.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2015-001852-32 Sponsor Protocol Number: 3475-164 Start Date*: 2015-12-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite I...
    Medical condition: Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005731-41 Sponsor Protocol Number: 3475-361 Start Date*: 2016-10-31
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Car...
    Medical condition: Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002837-23 Sponsor Protocol Number: 19062015 Start Date*: 2016-05-20
    Sponsor Name:University of Oxford
    Full Title: Low-dose Glibenclamide in Type 2 Diabetes Mellitus - Part A (LEGEND-A)
    Medical condition: Type 2 diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008208-42 Sponsor Protocol Number: 08/0168 Start Date*: 2009-06-26
    Sponsor Name:UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
    Full Title: A Randomised, Double-Blind Placebo-Controlled Pilot Study Assessing the Safety and Tolerability of Arimoclomol in Adult with Sporadic Inclusion Body Myositis
    Medical condition: The research project proposes to investigate Sporadic Inclusion Body Myositis (IBM). IBM is the commonest acquired disease of muscle affecting people aged 50 years and over. It is a progressive and...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066407 Inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002056-25 Sponsor Protocol Number: MK-8521-004 Start Date*: 2016-09-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects with Type 2 Diabete...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005054-36 Sponsor Protocol Number: MK-1029-015 Start Date*: 2016-08-22
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects with Persistent Asthma That is Uncontrolled While Receiving M...
    Medical condition: Persistent asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002406-37 Sponsor Protocol Number: 170 Start Date*: 2016-02-24
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc
    Full Title: A Phase 2 Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
    Medical condition: relapsed or refractory Primary Mediastinal Large B-Cell Lymphoma or Relapsed or Refractory Richter Syndrome (rrRS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036710 Primary mediastinal large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) PL (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002427-26 Sponsor Protocol Number: 3475-180 Start Date*: 2016-02-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Study of Pembrolizumab Monotherapy in Third-Line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Si...
    Medical condition: Esophageal Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003644-40 Sponsor Protocol Number: MK-3475-199 Start Date*: 2016-06-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) IE (Completed) DE (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) PL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004525-27 Sponsor Protocol Number: MK-0859-020 Start Date*: 2012-03-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Wi...
    Medical condition: Heterozygous Familial Hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001483-19 Sponsor Protocol Number: MK-3682-021 Start Date*: 2016-01-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects with...
    Medical condition: Hepatitis C infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002024-89 Sponsor Protocol Number: 3475-177 Start Date*: 2015-12-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
    Medical condition: Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) FI (Completed) SE (Completed) IE (Completed) DK (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003582-34 Sponsor Protocol Number: MK8835-002 Start Date*: 2014-05-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With...
    Medical condition: Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metaformin
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) HU (Completed) SK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-003697-26 Sponsor Protocol Number: MK8835-006 Start Date*: 2014-07-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of ...
    Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin and sitagliptin.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) FI (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-001892-35 Sponsor Protocol Number: MK-7339-009 Start Date*: 2019-12-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab ...
    Medical condition: Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004325-14 Sponsor Protocol Number: MK8342B-059 Start Date*: 2016-04-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women with Moderate to Severe Primary Dysmenorrhea (with Optional ...
    Medical condition: Treatment of primary dysmenorrhea
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004872 10062851 Primary dysmenorrhea LLT
    18.1 100000004872 10013934 Dysmenorrhea LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2019-002034-36 Sponsor Protocol Number: V937-011 Start Date*: 2019-12-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metas...
    Medical condition: Advanced/metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002321-29 Sponsor Protocol Number: MK-7264-042 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence
    Medical condition: Chronic Cough and Stress Urinary Incontinence
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    20.0 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003788-70 Sponsor Protocol Number: V114-026 Start Date*: 2019-07-15
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Phase 3, Multicenter, Randomized, Double-blind, Active-comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-E...
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061353 Pneumococcal infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) NO (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002950-38 Sponsor Protocol Number: MK-3475-051 Start Date*: 2014-11-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
    Medical condition: Treatment of advanced melanoma or advanced, relapsed or refractory PD-L1 positive malignant solid tumor or lymphoma in children from 6 months to less than 18 years old.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 21:24:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA